Abbott Laboratories (ABT) Shareholder Public Employees Retirement System Of Ohio Decreased Its Stake as Shares Rose

Abbott Laboratories (NYSE:ABT) Corporate LogoBig Money Sentiment increased to 0.86 in Q2 2018. It has change of 0.03, from 2018Q1’s 0.83. The ratio is positive due to ABT positioning: 41 sold and 583 reduced. 117 funds took positions and 420 increased positions. Investors holded 1.22 billion in 2018Q1 but now own 1.23 billion shares or 0.63% more. Rodgers Brothers Inc has invested 2.25% in Abbott Laboratories (NYSE:ABT). Stadion Money Mgmt Ltd Liability Com holds 0.05% in Abbott Laboratories (NYSE:ABT) or 23,658 shs. Dumont And Blake Invest Advisors Ltd Limited Liability Company reported 0.46% in Abbott Laboratories (NYSE:ABT). Puzo Michael J reported 2.53% in Abbott Laboratories (NYSE:ABT). Verity Verity Limited Liability holds 2% or 124,071 shs. Norinchukin National Bank The holds 0.26% in Abbott Laboratories (NYSE:ABT) or 288,888 shs. Shelter Insur Retirement Plan holds 67,300 shs. First City Capital owns 12,670 shs. Oppenheimer Asset Management owns 347,372 shs for 0.52% of their capital. Williams Jones & Associate holds 0.19% or 143,545 shs in its capital. Moreover, North Star Asset Mngmt Incorporated has 1.44% invested in Abbott Laboratories (NYSE:ABT) for 275,593 shs. The New York-based Cohen Klingenstein Ltd has invested 0.18% in Abbott Laboratories (NYSE:ABT). 16,469 are held by Columbia Asset. D L Carlson Invest Gp has 0.52% invested in Abbott Laboratories (NYSE:ABT) for 27,666 shs. Texas Cap Bancshares Tx holds 0.89% or 5,471 shs in its capital.

ABT had 13 selling transactions and 0 insider buys since July 21, 2018. This’s net activity of $30.08 million. Watkin Jared sold $4.62 million worth of stock. Shares for $66,601 were sold by PEDERSON MICHAEL J on Saturday, July 21. $366,957 worth of stock was sold by Salvadori Daniel Gesua Sive on Friday, September 28. CAPEK JOHN M also sold $4.22 million worth of Abbott Laboratories (NYSE:ABT) on Wednesday, July 25. Shares for $4.30 million were sold by Contreras Jaime on Wednesday, August 29. On Friday, September 28 $127,044 worth of stock was sold by Bracken Sharon J.

The holdings In Abbott Laboratories (ABT) was decreased held by Public Employees Retirement System Of Ohio. According to 2018Q2 SEC form the reduction is 4.17%. The company’s stock popped up 6.93% while Public Employees Retirement System Of Ohio sold 51,900 shares. The major pharmaceuticals company at the end of 2018Q2 was priced at $72.67M. It’s down from 1.24M at the end of the previous reported quarter. Now it had 1.19M shares held by the institutional investor . Abbott Laboratories has $122.86B market cap. Ticker’s shares touched $69.95 during the last trading session after 2.22% change.Abbott Laboratories has 7.95M shares volume, 16.84% up from normal. ABT is uptrending and has moved 28.17% since December 8, 2017. ABT outperformed the S&P500 by 12.55%.

According to a filing the Public Employees Retirement System Of Ohio’s stake in Synovus Financial Corp (NYSE:SNV) was rose by 72,061 shares to 167,900 shares valued at $8.87M in 2018Q2. It manages about $19.75B US Long portfolio. Public Employees Retirement System Of Ohio has risen its stake in Avista Corp (NYSE:AVA) and also increased its holding in Kemper Corp (NYSE:KMPR) by 48,271 shares in the quarter, for a total of 57,876 shares.

On January, 23 WallStreet expected Abbott Laboratories (NYSE:ABT)’s earnings release, according to RTT. Analysts forecast 9.46 % diference or $0.81 from the $0.74 EPS from 2017. If the current EPS of $0.81 is accurate, ABT’s profit could be $1.42B. Last quarter $0.75 EPS was reported. Analysts forecasts 8.00 % EPS growth this quarter.

For more Abbott Laboratories (NYSE:ABT) news released briefly go to:,,, or The titles are as follows: “SEC settles insider trading claims against former chief at Advanced Medical Optics – Seeking Alpha” released on November 13, 2018, “FDA issues new draft guidance for blood glucose monitors – Seeking Alpha” on November 29, 2018, “Know Labs Announces Laboratory Comparison Tests of Its UBAND Non-Invasive Blood Glucose Technology and Abbott Labs FreeStyle Libre – Business Wire” with a publish date: December 06, 2018, “FDA to reboot 510(k) process for devices – Seeking Alpha” and the last “Expect Diagnostics And Medical Devices Business To Drive Abbott’s Near-Term Earnings Growth – Forbes” with publication date: November 28, 2018.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

A total of 10 analysts rate Abbott Laboratories (NYSE:ABT) as follows: 10 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NYSE:ABT) has 11 ratings reports on Dec 8, 2018 according to StockzIntelligence. In Friday, November 30 report Goldman Sachs upgraded the stock to “Buy” rating. On Thursday, October 11 Morgan Stanley maintained Abbott Laboratories (NYSE:ABT) with “Overweight” rating. In Thursday, October 18 report Raymond James maintained the stock with “Outperform” rating. On Monday, September 24 the company was maintained by Wells Fargo. The company rating was maintained by Stifel Nicolaus on Thursday, July 19. On Monday, October 8 the rating was maintained by JP Morgan with “Overweight”. On Monday, September 24 the firm has “Outperform” rating given by Raymond James.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.